Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INFI

Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis

Infinity Pharmaceuticals logo

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.13
52-Week Range
N/A
Volume
2.48 million shs
Average Volume
2.58 million shs
Market Capitalization
$726,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INFI Stock News Headlines

🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.
See More Headlines

INFI Stock Analysis - Frequently Asked Questions

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The biotechnology company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.45 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Infinity Pharmaceuticals investors own include Digital Turbine (APPS), ChargePoint (CHPT), CrowdStrike (CRWD), Vuzix (VUZI) and Sangamo Therapeutics (SGMO).

Company Calendar

Last Earnings
11/02/2021
Today
4/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INFI
Employees
30
Year Founded
2000

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,370,000.00
Net Margins
-1,593.93%
Pretax Margin
-1,593.93%

Debt

Sales & Book Value

Annual Sales
$2.59 million
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
N/A

Miscellaneous

Free Float
81,857,000
Market Cap
$726,000.00
Optionable
Optionable
Beta
1.63

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INFI) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners